Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsSolute carrier family 22 member 18 (SLC22A18), which is a member of solute carrier family, is a protein encoded by the SLC22A18 gene in humans. This gene is within an important tumor suppressor gene region, which is one of several tumor suppressor-transferable fragments in the 11p15.5 gene domain. Mutations of this gene are involved in Wilms tumor, rhabdomyosarcoma, Beckwith-Wiedemann syndrome, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignant tumors and diseases involving the region, as well as transport chloroquine and quinine-related compounds in the kidney. Two alternative transcripts encoding the same contour have been described.
| Basic Information of SLC22A18 | |
| Protein Name | Solute carrier family 22 member 18 |
| Gene Name | SLC22A18 |
| Aliases | Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene A protein, Efflux transporter-like protein, Imprinted multi-membrane-spanning polyspecific transporter-related protein 1, Organic cation transporter-like protein 2 (ORCTL-2), Solute carrier family 22 member 1-like, Tumor-suppressing STF cDNA 5 protein, Tumor-suppressing subchromosomal transferable fragment candidate gene 5 protein, p45-Beckwith-Wiedemann region 1 A (p45-BWR1A) |
| Organism | Homo sapiens (Human) |
| UniProt ID | Q96BI1 |
| Transmembrane Times | 10 |
| Length (aa) | 424 |
| Sequence | MQGARAPRDQGRSPGRMSALGRSSVILLTYVLAATELTCLFMQFSIVPYLSRKLGLDSIAFGYLQTTFGVLQLLGGPVFGRFADQRGARAALTLSFLAALALYLLLAAASSPALPGVYLLFASRLPGALMHTLPAAQMVITDLSAPEERPAALGRLGLCFGVGVILGSLLGGTLVSAYGIQCPAILAALATLLGAVLSFTCIPASTKGAKTDAQAPLPGGPRASVFDLKAIASLLRLPDVPRIFLVKVASNCPTGLFMVMFSIISMDFFQLEAAQAGYLMSFFGLLQMVTQGLVIGQLSSHFSEEVLLRASVLVFIVVGLAMAWMSSVFHFCLLVPGLVFSLCTLNVVTDSMLIKAVSTSDTGTMLGLCASVQPLLRTLGPTVGGLLYRSFGVPVFGHVQVAINTLVLLVLWRKPMPQRKDKVR |
SLC22A18 is considered to be based on its chromosomal location at 11p15.5, mutations and abnormal splicing in several types of cancer, and downregulation of glioblastoma. Explosion homology analysis indicated that SLC22A18 is a member of the multispecific transporter and multidrug resistance gene family. Recently, SLC22A18 has been shown to be a tumor suppressor and a substrate for RING105. Structural mutations in SLC22A18 are rare, with individual point mutations reported in breast cancer cell lines, rhabdomyosarcoma cell lines, and Wilm's tumors and lung tumors. At the same time, the apparent deletion of hepatoblastoma and the loss of heterozygosity of hepatoma were also reported, suggesting that SLC22A18 may play a role in tumorigenesis.
Fig.1 The structure of SLC22A18 Protein.
The authors propose that SLC22A18 is potentially a marker of diagnostic and prognostic values.
This article reveals that SLC22A18 is an important tumor suppressor of gliomas, associated with decreased development and progression of gliomas by promoter methylation.
These results indicate that the lack of SLC22A18 protein expression is a better predictive tumor biomarker in patients with GBM who are treated with temozolomide, compared with promoter methylation.
These results indicate that SLC22A18 has a function of promoting apoptosis in glioma cells.
The results show that SLC22A18 may be an organic cation transporter, but the identity of its physiological substrates is undefined.
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC22A18 antibody development services.
Creative Biolabs' skillful scientists are glad to leverage our expertise and advanced technologies to help you with the member protein research. If you are interested, please feel free to contact us for more details.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
